The deficiency of blood coagulation factor IX (FIX) is congenital disorder leads to Gene therapy during neonatal and infant stages is a promising approach for hemophilia B. In spite of advancements of neonatal concentrated consideration medication, it is as yet troublesome or difficult to treat a few acquired genetic disorders utilizing regular pharmacological strategies. Quality treatment is a promising substitute methodology for treating an assortment of genetic disorders. When the patient achieves adulthood, be that as it may, it is regularly past the point of no return for powerful treatment. Be that as it may, in a few of these cases, neonatal gene therapy appears potentially useful against inherited disorders that are not obviously treatable through any other methods. This part depicts the methodology for neonatal quality treatment for acquired issue and displays preclinical neonatal quality treatment information for two acquired issue, metachromatic leukodystrophy and hypophosphatasia.
